Nature Cancer

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

Retrieved on: 
星期一, 十二月 18, 2023
Drug development, ACHL, Francis Crick Institute, Therapy, AI, Artificial intelligence, Nature Cancer, Bias, Algorithm, Vaccine

The article, entitled Breaking the performance ceiling for neoantigen immunogenicity prediction , makes the case that the efficient and accurate selection of immunogenic neoantigens is a critical determinant in neoantigen-based personalized tumor therapies.

Key Points: 
  • The article, entitled Breaking the performance ceiling for neoantigen immunogenicity prediction , makes the case that the efficient and accurate selection of immunogenic neoantigens is a critical determinant in neoantigen-based personalized tumor therapies.
  • The authors of the ‘Comment’ are all researchers affiliated with the DECOD-Ag consortium of which Achilles Therapeutics is a member.
  • Co-author Dr Sergio Quezada, Chief Scientific Officer of Achilles, commented: “Accurate prediction of neoantigen immunogenicity can be pivotal in determining the efficacy of immunological treatments.
  • It is therefore essential that we collaborate to refine our prediction models and improve the precision of our T cell therapies.”

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

Retrieved on: 
星期二, 十月 31, 2023
ASX, Stomach, FDA, CAR, Metastasis, CDH17, IND, Food, Gastrointestinal cancer, University, Doctor of Philosophy, Penns, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glomus tumor, Nature Cancer, Colorectal cancer, Clinical trial, Perelman School of Medicine at the University of Pennsylvania, University of Chicago, Immunotherapy, Cancer, Patient, Toxicity, Neoplasm, CHM, Investigational New Drug, Pharmaceutical industry, Medical imaging, Chimera, MD, Medicine

FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy

Key Points: 
  • FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy
    Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours
    SYDNEY, Oct. 31, 2023 /PRNewswire/ -- Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
  • The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • CHM 2101 is a 3rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • With the FDA IND clearance Chimeric will now begin the initiation of a phase 1 /2 multi-site clinical trial in patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

Newfound Mechanism Suggests Drug Combination Could Starve Pancreatic Cancer

Retrieved on: 
星期一, 十月 9, 2023
University of British Columbia, Doctor of Philosophy, Division, New York University Grossman School of Medicine, DON, Kimmelman, Glutaminase, MD, PDAC, Lustgarten Foundation for Pancreatic Cancer Research, Toxicity, Biochemistry, National Cancer Institute, Lung cancer, University, Survival, NYU Langone Health, Nature Cancer, Cancer, Therapy, Glutamine, Environment, Growth, Oxygen, ERK, Mouse, NYU, Pancreatic cancer, Neoplasm, Molecular biology, Enzyme, Radiation therapy, Medical imaging, Pharmaceutical industry

NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

Key Points: 
  • NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
  • Published online October 9 in Nature Cancer, the new study involves a drug designed to prevent pancreatic ductal adenocarcinoma (PDAC) cells from one such switch.
  • DON was designed to starve cancer cells by mimicking glutamine, which unlike glutaminase blockers, broadly inhibits all metabolic pathways that use glutamine.
  • In the current study, DRP-104 treatment alone decreased PDAC growth in mouse models of pancreatic cancer.

Genomic Analysis Reveals Ancient Cancer Lineages in Clams

Retrieved on: 
星期一, 十月 2, 2023
Columbia University, Clam, Human, University, National Human Genome Research Institute, Nature Cancer, Instability, FISU World University Games, Texas A&M University, Cancer, Mutation, Pacific Northwest Diabetes Research Institute, Assistant, Universidad, University of Maine at Machias, Compostela, University of Washington School of Medicine, Environment, Vaccine, Aquaculture

SEATTLE, Oct. 2, 2023 /PRNewswire-PRWeb/ -- In a new study published in the journal Nature Cancer, Michael Metzger, Ph.D., Assistant Investigator at Pacific Northwest Research Institute (PNRI), and a global team of co-investigators have conducted a comprehensive analysis of the genomic changes associated with a unique cancer in clams. The cancer is "transmissible" in that the cancer cells themselves jump from one clam to another through the environment. The study traced the evolution of the cancer cells over the last 200 years and revealed widespread genomic mutations and instability, which may explain how they have survived for so long. These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.

Key Points: 
  • The cancer is "transmissible" in that the cancer cells themselves jump from one clam to another through the environment.
  • These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.
  • These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.
  • The genomic analysis of cancer in clams advances current knowledge of cancer biology and underscores the importance of studying contagious cancers in their natural settings.

Recent Nature publications highlight the groundbreaking performance of RareCyte's Orion Spatial Biology platform

Retrieved on: 
星期二, 九月 26, 2023
University, CRC, Progression-free survival, MSS, Survival, Liquid biopsy, NewYork-Presbyterian Hospital, Research, Harvard Medical School, CLIA, Massachusetts General Hospital, Professor, Publication, Patient, Colorectal cancer, Weill Cornell Medicine, Neoplasm, Hospital, Oncogene, University of Sydney, Recurrence, Neoadjuvant therapy, Medical imaging, Nature, Nature Cancer

SEATTLE, Sept. 26, 2023 /PRNewswire/ -- In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.

Key Points: 
  • SEATTLE, Sept. 26, 2023 /PRNewswire/ -- In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.
  • Recent publications of pioneering findings in Nature journals, by leading translational and clinical institutions using the Orion multiplex imaging platform, demonstrate improved methods to help predict patient outcomes and to track the efficacy of novel therapies designed to shrink tumors ahead of resection.
  • Automated generation and ranking of spatial biomarkers revealed novel markers that are highly predictive of progression-free survival.
  • The global adoption of Orion for spatial biology research is a continuation of RareCyte's legacy of supporting important studies across all therapeutic areas, with a special focus on oncology.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on: 
星期二, 九月 19, 2023
TNBC, CRISPR, PBCC, Cell biology, University, Molecule, Nature Cancer, ACSS2, Culture, Genomics, DP2, HER2, Wistar, Breast, Infection, HIC, Cancer, Biomedical Research, Immunity, Jim Valvano, Research, Zhug, Bangladesh Technical Education Board, Ellen, National Cancer Institute, Triple-negative breast cancer, Patient, Metabolism, Wistar Institute, Immune system, University of Bologna, NCI, P30, NIH, Breast cancer, Vaccine

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points: 
  • Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
  • Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
  • The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
  • TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.

Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

Retrieved on: 
星期二, 八月 8, 2023
Lymphoma, TST, CD25, Nature Cancer, Pharmaceutical innovations, Food and Drug Administration, Cancer, Immunity, Toxicity, Antibody, HKEX, Patient, Interleukin 2, GZMB, Ophthalmology, Immune system, Neoplasm, Cytokine, PD-1, IL2, TeST TST-13 Junior, Food, Safety, Vaccine, Pharmaceutical industry, Palladium, Regulatory T cell

and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7).

Key Points: 
  • and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7).
  • Interleukin 2 (Interleukin-2, IL-2) is the first cytokine to be discovered and identified as playing a pivotal role in T-cell growth and expansion.
  • In contrast, "not-α" IL-2 is prone to expand CD25 negative bystander T cells, and this limits its anti-tumor efficacy.
  • The corresponding author, Dr. Kaijie He of Innovent Biologics stated, "We are very pleased that the results of this study are published and highlighted in the current issue of Nature Cancer.